pas-004
pas-004: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Pasithea Therapeutics Corp. (KTTA) | Phase 1 |
Clinical Trials (1)
A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in Patients With MAPK Pathway-driven Advanced Solid Tumors With a Documented RAS, NF1, or RAF Mutation or Patients Who Have Failed BRAF/MEK Inhibition
Frequently asked questions
Who is developing pas-004?
pas-004 is being developed by Pasithea Therapeutics Corp..
How many clinical trials involve pas-004?
BioSniper tracks 1 clinical trial involving pas-004.
Get deeper analysis on pas-004
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis